277 related articles for article (PubMed ID: 35921970)
1. Immunotherapy of cholangiocarcinoma: Therapeutic strategies and predictive biomarkers.
Chen R; Zheng D; Li Q; Xu S; Ye C; Jiang Q; Yan F; Jia Y; Zhang X; Ruan J
Cancer Lett; 2022 Oct; 546():215853. PubMed ID: 35921970
[TBL] [Abstract][Full Text] [Related]
2. Tumor immune microenvironment and the current immunotherapy of cholangiocarcinoma (Review).
Yang S; Zou R; Dai Y; Hu Y; Li F; Hu H
Int J Oncol; 2023 Dec; 63(6):. PubMed ID: 37888583
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint inhibitors and combinations with other agents in cholangiocarcinoma.
Skouteris N; Papageorgiou G; Fioretzaki R; Schizas D; Kykalos S; Tolia M; Charalampakis N
Immunotherapy; 2023 May; 15(7):487-502. PubMed ID: 36876442
[TBL] [Abstract][Full Text] [Related]
4. Immune checkpoints and their promising prospect in cholangiocarcinoma treatment in combination with other therapeutic approaches.
Vatankhah F; Salimi N; Khalaji A; Baradaran B
Int Immunopharmacol; 2023 Jan; 114():109526. PubMed ID: 36481527
[TBL] [Abstract][Full Text] [Related]
5. The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine.
Rimassa L; Personeni N; Aghemo A; Lleo A
J Autoimmun; 2019 Jun; 100():17-26. PubMed ID: 30862450
[TBL] [Abstract][Full Text] [Related]
6. Cholangiocarcinoma - novel biological insights and therapeutic strategies.
Ilyas SI; Affo S; Goyal L; Lamarca A; Sapisochin G; Yang JD; Gores GJ
Nat Rev Clin Oncol; 2023 Jul; 20(7):470-486. PubMed ID: 37188899
[TBL] [Abstract][Full Text] [Related]
7. Tertiary lymphoid structures predict the prognosis and immunotherapy response of cholangiocarcinoma.
Shang T; Jiang T; Lu T; Wang H; Cui X; Pan Y; Xu M; Pei M; Ding Z; Feng X; Lin Y; Li X; Tan Y; Feng F; Dong H; Wang H; Dong L
Front Immunol; 2023; 14():1166497. PubMed ID: 37234171
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy in cholangiocarcinoma.
Al-Rajabi R; Sun W
Curr Opin Gastroenterol; 2021 Mar; 37(2):105-111. PubMed ID: 33507028
[TBL] [Abstract][Full Text] [Related]
9. Tumor Microenvironment and its Implications for Antitumor Immunity in Cholangiocarcinoma: Future Perspectives for Novel Therapies.
Cao H; Huang T; Dai M; Kong X; Liu H; Zheng Z; Sun G; Sun G; Rong D; Jin Z; Tang W; Xia Y
Int J Biol Sci; 2022; 18(14):5369-5390. PubMed ID: 36147461
[TBL] [Abstract][Full Text] [Related]
10. Immunosuppressive tumor microenvironment in occupational cholangiocarcinoma: Supportive evidence for the efficacy of immune checkpoint inhibitor therapy.
Sato Y; Tanaka S; Kinoshita M; Takemura S; Shinkawa H; Kokudo T; Hasegawa K; Tanaka H; Yoshimoto H; Mori A; Yamamura M; Sasaki M; Harada K; Kubo S
J Hepatobiliary Pancreat Sci; 2020 Nov; 27(11):860-869. PubMed ID: 32506715
[TBL] [Abstract][Full Text] [Related]
11. Biologics, Immunotherapy, and Future Directions in the Treatment of Advanced Cholangiocarcinoma.
Saeed A; Park R; Al-Jumayli M; Al-Rajabi R; Sun W
Clin Colorectal Cancer; 2019 Jun; 18(2):81-90. PubMed ID: 30905548
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy for cholangiocarcinoma: a 2021 update.
Charalampakis N; Papageorgiou G; Tsakatikas S; Fioretzaki R; Kole C; Kykalos S; Tolia M; Schizas D
Immunotherapy; 2021 Sep; 13(13):1113-1134. PubMed ID: 34190581
[TBL] [Abstract][Full Text] [Related]
13. Immunology and immunotherapy of cholangiocarcinoma.
Greten TF; Schwabe R; Bardeesy N; Ma L; Goyal L; Kelley RK; Wang XW
Nat Rev Gastroenterol Hepatol; 2023 Jun; 20(6):349-365. PubMed ID: 36697706
[TBL] [Abstract][Full Text] [Related]
14. Revisiting targeted therapy and immunotherapy for advanced cholangiocarcinoma.
Du J; Lv X; Zhang Z; Huang Z; Zhang E
Front Immunol; 2023; 14():1142690. PubMed ID: 36936931
[TBL] [Abstract][Full Text] [Related]
15. Targeting the tumor microenvironment in cholangiocarcinoma: implications for therapy.
Louis C; Edeline J; Coulouarn C
Expert Opin Ther Targets; 2021 Feb; 25(2):153-162. PubMed ID: 33502260
[No Abstract] [Full Text] [Related]
16. The role of tumor-infiltrating lymphocytes in cholangiocarcinoma.
Liu D; Heij LR; Czigany Z; Dahl E; Lang SA; Ulmer TF; Luedde T; Neumann UP; Bednarsch J
J Exp Clin Cancer Res; 2022 Apr; 41(1):127. PubMed ID: 35392957
[TBL] [Abstract][Full Text] [Related]
17. Syngeneic murine models with distinct immune microenvironments represent subsets of human intrahepatic cholangiocarcinoma.
Tomlinson JL; Li B; Yang J; Loeuillard E; Stumpf HE; Kuipers H; Watkins R; Carlson DM; Willhite J; O'Brien DR; Graham RP; Chen X; Smoot RL; Dong H; Gores GJ; Ilyas SI
J Hepatol; 2024 Jun; 80(6):892-903. PubMed ID: 38458319
[TBL] [Abstract][Full Text] [Related]
18. Advances in immunotherapy for biliary tract cancers.
Zhao Y; Yang M; Feng J; Wang X; Liu Y
Chin Med J (Engl); 2024 Mar; 137(5):524-532. PubMed ID: 37646139
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis.
Clements O; Eliahoo J; Kim JU; Taylor-Robinson SD; Khan SA
J Hepatol; 2020 Jan; 72(1):95-103. PubMed ID: 31536748
[TBL] [Abstract][Full Text] [Related]
20. Unveiling the immunogenomic landscape of cholangiocarcinoma: Identifying new prognostic markers and therapeutic targets based on CCL5 expression.
Wang J; Xiang D; Dai Z; Zhu J; Du Y; Fu G; Chu X
J Gene Med; 2024 Jan; 26(1):e3630. PubMed ID: 37985959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]